FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, in particular to an anti-idiotypic antibody or its antigen-binding fragment, its production method, as well as to a conjugate containing it, a composition, and a kit. A nucleic acid molecule encoding a heavy chain and/or a light chain of the above-mentioned antibody or its fragment, as well as a vector and a cell containing it are also disclosed. The invention also relates to a purification method, a detection method, a selection method, a method for the production of a cell composition, as well as to a depletion method and to a stimulation method, providing for the use of the above-mentioned antibody or its fragment.
EFFECT: invention is effective for the treatment of a disease or a disorder, in which CD19 is expressed.
52 cl, 15 dwg, 3 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES TO CHIMERIC ANTIGEN RECEPTORS DERIVED FROM 4G7 | 2020 |
|
RU2826051C2 |
| REAGENTS FOR REPRODUCTION OF CELLS EXPRESSING RECOMBINANT RECEPTORS | 2018 |
|
RU2783956C2 |
| HUMAN ANTIBODIES BINDING TO ROR2 | 2018 |
|
RU2784586C2 |
| NEW CHIMERIC ANTIGEN RECEPTOR CONSTRUCTS CONTAINING TNFR2 DOMAINS | 2019 |
|
RU2808254C2 |
| TYPES OF COMBINATION THERAPY USING CHIMERIC ANTIGEN RECEPTORS AND PD-1 INHIBITORS | 2017 |
|
RU2809160C2 |
| CHIMERIC ANTIGENE RECEPTORS TARGETTING FLT3 | 2018 |
|
RU2820859C2 |
| CHIMERIC ANTIGENIC (CAR) RECEPTOR AGAINST CD123 FOR USE IN TREATING MALIGNANT TUMORS | 2015 |
|
RU2724999C2 |
| CHIMERIC ANTIBODY/T-CELL RECEPTOR STRUCTURES AND THEIR APPLICATIONS | 2016 |
|
RU2767209C2 |
| SPECIFIC TO MUCIN-1 POLYPEPTIDE AND ITS USE | 2021 |
|
RU2805840C1 |
| CHIMERIC ANTIGENE RECEPTOR | 2019 |
|
RU2810092C2 |
